What are ADC's

Our services

ADC Review
is made possible by:

NCT01432353 (Clinical Trial / DFRF4539A / RG-7598)

Study Title
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (NCT01432353)

Trial Description
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of the antibody-drug conjugate DFRF4539A (RG-7598) in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly.

Patients exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to 17 cycles. Anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • DFRF4539A
  • Phase: I
  • Enrollment: 39
  • Start: September 2011
  • Completion: April 2014
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 13, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar